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disease (CKD) whatever the initial etiology is. Sustained
inflammatory cell infiltration, epithelial decomposition,
microvascular rarefaction, and pericyteemyofibroblast
transition lead to renal fibrosis and failure.1,2 Erythropoi-
etin (EPO), mainly produced in the kidney after birth, can
regulate the production of red blood cells to maintain tis-
sue oxygenation. However, the production of EPO is
decreased in patients with CKD. Thus far, therapeutic ef-
forts by administering EPO in patients with CKD have been
made only to correct anemia and putative hypoxic tissue
damage. With increasing number of patients with CKD
receiving EPO treatment, emerging evidence suggests that
EPO not only has erythropoietic function, but also has
renoprotective potentials.3
Existing evidence suggests that the pleiotropic effects
of EPO are mediated by distinct receptors: erythropoiesis
through the EPO receptor (EPOR) homodimer and tissue
protection through a heterocomplex composed of EPOR
and b-common receptor (bcR also known as CD131).4
Although the EPORebcR heterodimer has been shown in
the brain and cultured cells by immunoprecipitation,
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Brines et al4 demonstrated that carbamylated EPO (CEPO),
an EPO derivative without EPOR affinity, has the same
tissue-protective effect, but not erythropoietic effect, as
EPO, whereas both CEPO and EPO lose the protective ef-
fect in the bcR knockout mice. Accordingly, bcR, not
EPOR, is indispensible for the tissue-protective effect of
EPO. Therefore, further studies are required to define the
other critical receptor subunit that constitutes a hetero-
receptor with bcR, thereby transducing the tissue-
protective signaling of EPO. In addition, the renal cells
responding to EPO in the injured kidney is a subject of
considerable debate. In contrast to the absence of intra-
cellular signaling in renal epithelial cells, EPO can induce
nitric oxide (NO) production through bcR-mediated acti-
vation of endothelial NO synthase (eNOS) in endothelial
cells.5,6 Noteworthily, activation of eNOSeNO signaling by
EPO needs an interaction between bcR and vascular
endothelial cell growth factor receptor 2. NO production
by endothelial cells can protect microvasculature from
rarefaction.6 In addition to endothelial cells, EPO can
inhibit the stimulation of pro-inflammatory genes including
tumor necrosis factor-a and inducible NOS by blocking the
activation of nuclear factor-kB (NF-kB).7 The immune-
modulatory effects of EPO may be of therapeutic rele-
vance in its renoprotective effect.
Macrophages and myofibroblasts are at the heart of
renal fibrosis.1,2 Macrophages could be polarized to& Formosan Medical Association. All rights reserved.
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according to the distinctive cytokine production and
behavior after different activation.2 In addition, exposure
to apoptotic cells or immune complexes can generate
macrophages that produce high levels of interleukin-(IL-10)
and are actively involved in the suppression of immune
responses. This macrophage subpopulation might be better
identified as a regulatory macrophage (Mreg).2 Our own
studies have shown macrophage subpopulations that are
derived from a single monocyte subset in mice with CKD
and that the wound-healing (M2) macrophages can secrete
cytokines to drive the pericyteemyofibroblast transition
and consequent renal fibrosis.1,2,8 Using a genetic model for
macrophage ablation in mice with CKD, we have discovered
the general role of macrophages in renal fibrosis.2,8
Administration of human serum amyloid P can inhibit
renal fibrosis through macrophage regulation and local
generation of IL-10.2 Because EPO can deactivate macro-
phages by inhibiting the activity of NF-kB, we propose that
one of the mechanisms underlying the antifibrotic effects
of EPO in CKD is macrophage regulation in vivo.
In summary, clinical evidence shows the renoprotective
potential of EPO in patients with CKD, but further clinical
studies are necessary to define when to start EPO treat-
ment and what is the optimal EPO dosage for slowing dis-
ease progression in patients with CKD. The application of
EPO treatment for renoprotection may need to be earlier
than that for erythropoiesis. Although current evidence
shows no expression and function of EPOR in kidney, it is
still possible for EPO to attenuate renal fibrosis through
macrophage regulation and endothelial cell protection
through the other unidentified bcR heterocomplexes.
Further bench work needs to be carried out in order to
clarify the cellular target of EPO in kidney and develop
novel EPO derivative or mimetic for renoprotection.Acknowledgments
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